Changes in blood pressure during treatment with the tyrosine kinase inhibitor lenvatinib.

Lenvatinib might lead to HT without fluid retention soon after the initiation of treatment, subsequently leading to a reduction in urinary sodium excretion, thereby contributing to a rise in BP by fluid retention.